USD 1.6bn investment to ensure supplies of sought-after Novo Nordisk drug
After a challenging launch of Wegovy, where Novo Nordisk couldn’t keep up with skyrocketing demand, the pharmaceutical firm is making a large investment to increase production.
by mikkel aabenhus hemmingsen, translated by catherine brett
Novo Nordisk will restart sales of obesity drug Wegovy (which is based on active ingredient semaglutide) in 2023, after its first launch was marred by an inability to keep with soaring demand.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
